Table 1.
General inclusion criteria in the literature
| Methods | FEV1 % pred | RV % pred | TLC % pred | PAB, mmHg | PaCO2 mmHg | 6MWT m | mMRC p | DLCO % | Smoking cessation |
|---|---|---|---|---|---|---|---|---|---|
| Valves13–20 | 15–50 | >175 | >100 | <50 | <60 | 100–500 | >2 | - | >6 Months |
| Coils24–33 | 15–45 | >175 | >100 | <50 | <55 | 150–450 | - | - | >8Weeks |
| TVA37–39 | 20–45 | >150 >200* |
>100 | <35 | <55 | >140 | - | >20 | >4 Months |
| BioLVR40,41 | <50 | >150 | >100 | <25 | <65 | >150 | - | 20–60 | >4 Months |
| TLD42,43 | 30–60 | - | - | <25 | <60 | - | - | - | >6 Months |
| ABS44–45 | <50 | >180 | - | <25 | <50 | - | >2 | >15 | >8 Weeks |
TVA: thermal vapor ablation; LVR: lung volume reduction; TLD: targeted lung denervation; ABS: airway bypass stent; FEV1: forced expiration volume in the 1 s; RV: residual volume; TLC: total lung capacity; PAB: pulmonary arterial pressure; PaCO2: arterial partial pressure of carbon dioxide; 6MWT: 6-minute walking test; mMRC: Modified British Medical Research Council; DLCO: diffusing capacity for carbon monoxide;
*
preferably